Acceleron's ACE-083 increases muscle volume in Phase II for Charcot-Marie-Tooth disease

Acceleron Pharma Inc. (NASDAQ:XLRN) reported preliminary data from 18 patients with Charcot-Marie-Tooth disease in Part 1 of a Phase II trial showing that ACE-083 increased mean total muscle volume by 12.6-14.2%, increased mean contractile muscle volume by 15.8-19.6% and decreased mean absolute fat fraction by 1.7-3.5%. Muscle volume was measured by MRI three weeks after the last injection. ACE-083 was generally well tolerated. Data were presented at the Peripheral Nerve Society meeting in Baltimore.

Patients in the open-label Part 1 of the U.S. trial received 150, 200 or 240 mg intramuscular ACE-083 every three weeks for three months...